Fibrosoft & Advanced Plastic Surgery Centre
- Biotech or pharma, therapeutic R&D
- Medical device or technology
- Other R&D services
- Academic, tech transfer
Fibrosoft: A novel non-surgical treatment of fibromatosis, including Dupuytren’s, Ledderhose’s and Peyronie’s diseases.
Introduction: Subcutaneous scarring and contracture affecting the hands -Dupuytren’s, feet-Ledderhose’s and penis-Peyronie’s are common. The incidence of Dupuytren’s contracture worldwide in individuals over 65 years is 32-35%. This incidence is higher in European countries. Conservatively, 28.8 million individuals have Dupuytren’s contracture in the USA, UK and Australia alone. Surgery is the gold standard and recovery painful and arduous.
270+ patients have been treated with 30% improvement following the first injection. The treatment is safe with no serious adverse events (SAEs) observed and zero CTN (Clinical trial notification).
The inventor is seeking a partnership/licensee/VC funding to exploit this attractive opportunity, conservatively valued at $1.2 Billion per annum.
Patent status
USA & Australia granted. European under accelerated prosecution.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}